Skip to content
AnalystLens

Cigna Group 8-K Report, Financial Results (May 2, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 2, 2024
Period End
May 2, 2024
Security
CI
In the record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Deal closed8-K · Feb ’19Feb ’19
  2. Material agreement8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’23May ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group's May 2, 2024 8-K furnishes its first-quarter 2024 earnings release and reports a GAAP shareholders' net loss of $277 milliona, or $0.97 per share, driven by a non-cash after-tax investment loss of $1.8 billion ($6.31 per share) tied to the impairment of its VillageMD equity securities.

On an adjusted basis, which management uses as its principal profitability measure, income from operations rose 16% year over year to $1.9 billionb, or $6.47 per share, versus $5.41 a year earlier. Total revenues grew 23% to $57.3 billion, largely from Evernorth Health Services' large client wins, and management raised its full-year 2024 adjusted income from operations outlook by $40 million to at least $8.065 billion, or at least $28.40 per share. The quality of the quarter is mixed beneath the headline.

Evernorth's adjusted pre-tax margin compressed to 2.9% from 3.6%, reflecting onboarding costs for new clients and a mix shift toward lower-margin pharmacy revenue, while Cigna Healthcare was the clear bright spot, with its medical care ratio improving to 79.9% from 81.3% and pre-tax margin expanding to 10.1%. The company also disclosed a cyber-related claims disruption that inflated Cigna Healthcare net medical costs payable to $5.66 billionc, and its debt-to-capitalization ratio rose to 44.3% from 40.1% after debt issuance tied to share repurchases. Investors should also note the pending sale of the Medicare businesses to HCSC, which cleared the Hart-Scott-Rodino waiting period and is expected to close in the first quarter of 2025, and the reorganization of Evernorth into the Pharmacy Benefit Services and Specialty and Care Services operating segments.

The filing itself is a routine furnishing of the earnings release under Item 2.02, and the substantive information lies in Exhibit 99.1. The key items for investors are the strength of Cigna Healthcare margins, the Evernorth margin trajectory as large new client relationships ramp, the cyber incident's effect on claims processing, and the company's leverage and buyback activity, including about $3.4 billiond of repurchases year to date and a final ASR settlement expected in the second quarter of 2024.

02—Key points

Key Highlights

  1. GAAP shareholders' net loss of $277 million ($0.97 per share), driven by a $1.8 billion after-tax non-cash impairment loss on VillageMD equity securities, versus net income of $1.3 billion ($4.24 per share) a year earlier.
  2. Adjusted income from operations rose 16% to $1.9 billion ($6.47 per share) from $1.6 billion ($5.41 per share) in Q1 2023.
  3. Total revenues increased 23% to $57.3 billion, led by Evernorth Health Services growth from several large client wins; Evernorth adjusted revenues rose 28%.
  4. Cigna Healthcare's medical care ratio improved to 79.9% from 81.3%, and its pre-tax adjusted margin expanded to 10.1% from 8.8%, though net medical costs payable rose to $5.66 billion due to a third-party cyber incident that disrupted claims processing.
  5. Evernorth's pre-tax adjusted margin fell to 2.9% from 3.6% on new-client onboarding costs and business mix, despite a 3% rise in pre-tax adjusted income.
  6. Full-year 2024 adjusted income from operations outlook raised by $40 million to at least $8.065 billion ($28.40 per share), with adjusted revenues guided to at least $235.0 billion.
  7. Debt-to-capitalization rose to 44.3% from 40.1%; the company repurchased 10.1 million shares for about $3.4 billion year to date, with ASR final settlement expected in Q2 2024.

03—Questions

Frequently Asked Questions

  1. Why did Cigna report a GAAP net loss in the first quarter of 2024?

    The loss of $277 million, or $0.97 per share, was mainly due to a non-cash after-tax investment loss of $1.8 billion ($6.31 per share) from the impairment of VillageMD equity securities. Excluding this and other non-operating items such as amortization of acquired intangibles and special items, adjusted income from operations was $1.9 billion, or $6.47 per share.

  2. What is driving the strong revenue growth at Evernorth?

    Evernorth's adjusted revenues rose 28% year over year to $46.2 billion, reflecting several large client wins, continued expansion of existing relationships, and strong organic growth in Specialty and Care Services. Total pharmacy customers also grew 25% sequentially to 122.8 million.

  3. Is Evernorth's profitability keeping pace with its revenue growth?

    Not fully. Evernorth's pre-tax adjusted income grew 3%, but its pre-tax adjusted margin fell to 2.9% from 3.6%. Management attributes this to onboarding costs for new clients, investments in digital capabilities and care solutions, and business mix, which includes lower-margin pharmacy revenue from the large client wins.

  4. What is the status of the Medicare business sale to HCSC?

    The Hart-Scott-Rodino waiting period expired on April 17, 2024, and the transaction remains on track to close in the first quarter of 2025.

  5. How is the company managing its capital and leverage?

    Debt-to-capitalization increased to 44.3% from 40.1% at year-end 2023, largely due to debt issuance timing tied to the accelerated share repurchase agreements. Cigna bought back 10.1 million shares for about $3.4 billion through May 1, 2024, with final ASR settlement expected in Q2 2024, and its 2024 outlook includes the effect of expected future repurchases.

04—Continue

← View all 8-K filings